Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 10
Submit an article Journal homepage
457
Views
36
CrossRef citations to date
0
Altmetric
Research Article

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation

Holger W. AunerCentre for Haematology, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UKCorrespondence[email protected]
,
Richard SzydloCentre for Haematology, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK
,
Alero RoneDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
,
Aristeidis ChaidosDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
,
Chrissy GilesDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
,
Ed KanferDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
,
Donald H. MacdonaldDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
,
David MarinCentre for Haematology, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK
,
Dragana MilojkovicDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
,
Jiri PavluDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
,
Jane F. ApperleyCentre for Haematology, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK
&
Amin RahemtullaDepartment of Clinical Haematology, Clinical Programme Group 6, Imperial College Healthcare NHS Trust, London, UK
 show all
Pages 2200-2204 | Received 07 Dec 2012, Accepted 03 Feb 2013, Published online: 04 Mar 2013

References

  • Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.
  • Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
  • Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789–793.
  • Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009;23:1904–1912.
  • Moreau P, Avet-Loiseau H, Harousseau JL, et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011;29:1898–1906.
  • Cook G, Liakopoulou E, Pearce R, et al. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011;17:1638–1645.
  • Jimenez-Zepeda VH, Mikhael J, Winter A, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012;18:773–779.
  • Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006;91:141–142.
  • Shah N, Ahmed F, Bashir Q, et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012;118:3549–3555.
  • Blimark C, Veskovski L, Westin J, et al. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation. Eur J Haematol 2011;87:117–122.
  • Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417–422.
  • Gonsalves WI, Gertz MA, Lacy MQ, et al. Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplant2012 Sep 24. [Epub ahead of print]
  • Morris TC, Velangi M, Jackson G, et al. Less than half of patients aged 65 years or under with myeloma proceed to transplantation: results of a two region population-based survey. Br J Haematol 2005;128:510–512.
  • Lemieux E, Hulin C, Caillot D, et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant 2012 Nov 24. [Epub ahead or print]
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20: 1467–1473.
  • Pavlu J, Auner HW, Ellis S, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol Oncol 2011;29:75–80.
  • Schmitz N, Buske C, Gisselbrecht C. Autologous stem cell transplantation in lymphoma. Semin Hematol 2007;44:234–245.
  • Saraf S, Chen YH, Dobogai LC, et al. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant 2006;37:1099–1102.
  • Verma PS, Howard RS, Weiss BM. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J Hematol 2008;83:355–358.
  • Hari PN, Majhail NS, Zhang MJ, et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2010;16:395–402.
  • Auner HW, Pavlu J, Szydlo R, et al. Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system. Br J Haematol 2012;157:125–127.
  • Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012;120:1060–1066.
  • Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 2012;120:1077–1086.
  • Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067–1076.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.